NCT07847112Not yet recruiting
Soluble TREM-1 in Diabetes-Associated Cardiovascular Complications
Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Diabetes-Associated Cardiovascular Complications
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
Cardiovascular disease is the leading cause of illness and death among individuals with type 2 diabetes mellitus (T2DM). Chronic low-grade inflammation contributes significantly to blood vessel damage, atherosclerosis, and diabetic heart complications. Although conventional inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and ferritin are commonly measured, they lack specificity and can be altered by various other health conditions. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is an innate immune receptor biomarker linked to cardiac injury and inflammation, but its diagnostic and predictive value in diabetes-associated cardiovascular complications is not yet well established. The primary purpose of this prospective observational study is to evaluate serum sTREM-1 as an immunoinflammatory biomarker for identifying cardiovascular complications in adults with type 2 diabetes, and to compare its diagnostic performance with hs-CRP and ferritin. Adult participants (aged 18-65 years) with established type 2 diabetes undergoing structured cardiac assessment will have a single venous blood sample drawn alongside their clinical examination, electrocardiogram (ECG), and echocardiogram. Biomarker levels will be compared between participants with confirmed cardiac complications (coronary artery disease, heart failure, or arrhythmias) and those without cardiac complications to determine whether sTREM-1 can improve early cardiovascular risk stratification.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 85 (estimated)
- First submitted
- 23 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- Assiut University
- NCT number
- NCT07847112
What you commit to
- Study type: Observational
- Planned participants: 85
- From Oct 2026 to the primary completion date, Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Autoimmune or chronic inflammatory disease receiving active treatment.
Other illness
- Type 1, gestational, or secondary diabetes.
- Active infection, sepsis, or acute inflammatory illness at the time of blood sampling.
- Known iron-overload states, hemochromatosis, active malignancy, or chronic liver disease.-
- Chronic kidney disease requiring dialysis.
Other
- Pregnancy.
- Refusal or inability to provide informed consent.
Who the study is looking for
- Adult patients aged 18 to 65 years.
- Established diagnosis of type 2 diabetes mellitus.
- Undergoing structured cardiology assessment (clinical evaluation, electrocardiogram \[ECG\], echocardiography, and further diagnostic testing as indicated) during the study period.
- Willingness to provide informed consent.
Age in the registry: 18 years to 65 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.